Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 19

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 19
---
 and whether APHEXDA receives adequate reimbursement from third-party payors; |

| • | our ability to establish, manage, and maintain corporate collaborations, as well as the ability of our collaborators to execute on their development and commercialization plans; |

| • | our ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; |

| • | the interpretation or characterization of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials; |

| • | the implementation of our business model and strategic plans for our business and therapeutic candidates; |

| • | the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; |

| • | estimates of our expenses, future revenues, capital requirements and our needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercialization of APHEXDA; |

| • | risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; |

| • | competitive companies, technologies and our industry; |

| • | our ability to maintain the listing of our ADSs on The Nasdaq Capital Market; |

| • | statements as to the impact of the political and security situation in Israel on our business, which may exacerbate the magnitude of the factors discussed above; and |

| • | those factors referred to in “Risk Factors,” in this Prospectus Supplement as well as in our most recent Annual Report on Form 20-F. |

S - 9 CAPITALIZATION The following table presents our capitalization as of September 30, 2024:

| • | on an actual basis; |

| • | on a pro forma basis after giving effect to (A) the sale in the November 2024 Registered Direct Offering (i) 4,121,493 ADSs, representing 61,822,395 ordinary shares, and warrants to purchase up to an aggregate of 2,060,746 ADSs,           
 representing 30,911,190 ordinary shares, at a combined purchase price of $0.5464 per ADS and associated warrant, and (ii) pre-funded warrants to purchase up to an aggregate of 12,349,956 ADSs, representing 185,249,340 ordinary shares, and 
 warrants to purchase up to an aggregate of 6,174,978 ADSs, representing 92,